Matthew S. Davids, MD, MMSc, Discusses Extended Use of Venetoclax in CLL
Matthew S. Davids, MD, MMSc, spoke about the benefit of venetoclax combinations in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Matthew S. Davids, MD, MMSc, Discusses Rationale for the MAJIC Study of Venetoclax Plus Acalabrutinib in CLL
Matthew S. Davids, MD, MMSc, spoke about using venetoclax plus acalabrutinib in the phase 3 MAJIC study for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Matthew S. Davids, MD, Discusses Important Abstracts Presented at ASH 2021
Matthew S. Davids, MD, spoke about which abstracts presented at ASH 2021 he felt were most important.
Matthew S. Davids, MD, MMSc, Discusses Study of Duvalisib in Combination with Venetoclax
Matthew S. Davids, MD, MMSc, discussed his phase I/II study of duvalisib combined with venetoclax for patients with relapsed/refractory CLL and SLL at the ASH Annual Meeting & Exposition.